Serge Debrus

Title: The Innovative Contributions of Serge Debrus

Introduction

Serge Debrus is a notable inventor based in Rixensart, Belgium. He has made significant contributions to the field of immunology, particularly in the development of vaccines. His work focuses on combating human papillomavirus (HPV), which is known to cause various types of cancer.

Latest Patents

Serge Debrus holds a patent for a vaccine against HPV types 16 and 18, as well as at least another HPV type selected from HPV 31, 45, or 52. The patent describes an immunogenic composition and methods for producing this composition, which includes virus-like particles (VLPs) from HPV 16 and 18. Notably, the dose of the VLP of the additional cancer types is reduced relative to that of HPV 16 or 18. This innovative approach aims to enhance the efficacy of the vaccine while minimizing potential side effects.

Career Highlights

Throughout his career, Serge has been associated with GlaxoSmithKline Biologicals SA, a leading company in the pharmaceutical industry. His work has contributed to advancements in vaccine development, particularly in the fight against HPV-related cancers. With a total of 1 patent, his contributions are recognized within the scientific community.

Collaborations

Serge Debrus has collaborated with esteemed colleagues, including Marie-Therese Martin and Robert John Stephen. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of vaccine research.

Conclusion

In summary, Serge Debrus is a prominent inventor whose work in vaccine development has the potential to significantly impact public health. His innovative approaches to combating HPV demonstrate the importance of research and collaboration in the fight against cancer.